As an enrichment strategy supplemented by the diagnostic framework of subjective cognitive decline (SCD), SCD plus identifies features that may increase the likelihood of including future-Alzheimer's disease (AD) patients. This study aimed to identify the shared and distinct atrophy patterns between patients specified by SCD plus and amnestic mild cognitive impairment (aMCI, a prodromal stage of AD) and to investigate the extent that automated brain magnetic resonance imaging (MRI) volumetry can differentiate patients with SCD from normal control (NC) participants and patients with aMCI. We acquired structural MRI brain scans from 44 patients with aMCI, 40 patients with SCD (who met the major criteria of SCD plus), and 48 NC participants. Automatic brain segmentation was performed to quantify the volumetric measures of cognitive-relevant areas. These volumetric measures were compared across the 3 groups with analysis of variance. In addition, we performed support vector machine analyses using volumetric measures of single regions or multiple regions to further evaluate the sensitivity of automated brain volumetry in differentiating a specific group from another. The atrophy patterns in patients with aMCI and SCD were similar. Using the regional volumetric measures, we achieved high performance in differentiating aMCI and SCD from NCs (average classification accuracy [ACC] > 90%). However, the performance was not ideal when differentiating aMCI from SCD (ACC < 63%). In conclusion, patients with SCD specified by SCD plus presented similar atrophy patterns as patients with aMCI, which was distinguishable from NC participants. Future studies should aim to associate the atrophy patterns of SCD with possible conversion to aMCI or AD in a longitudinal design.
Introduction
Alzheimer's disease (AD) has been associated with multiple pathophysiological processes in the brain initiated many years prior to the first onset of cognitive symptoms. As a prodromal stage of AD, amnestic mild cognitive impairment (aMCI) presents with early memory impairment relative to age-matched and education-matched healthy people and largely impacts activities of daily life. 1 Subjective cognitive decline (SCD), that is, self-perceived cognitive decline while maintaining normal performance in objective cognitive assessment, 2 has been suggested as an even earlier symptomatic disease stage of AD than aMCI. 3 Therefore, there has been increasing research interest in characterizing the functional 4, 5 and structural [6] [7] [8] changes in the brains of patients with SCD to determine a better population definition for future dementia prevention trials. With regard to structural magnetic resonance imaging (MRI) research, researchers have reported an association between brain structural deficits (eg, in the gray matter and hippocampal regions) and the onset of SCD. 7, 9, 10 The brain regions with atrophy in patients with SCD largely follow the AD-like atrophy pattern (notably in the medial temporal lobe), which are also present in patients with aMCI. 8 To further investigate the degree of brain volume loss among different early stages of AD, many studies applied machine learning approaches to differentiate patients with SCD or MCI from normal control (NC) participants. In these studies, differentiating aMCI from NCs [11] [12] [13] (classification accuracy >90%) was much easier than differentiating SCD from NCs 7 (classification accuracy <68%) using brain atrophy measures.
Of note, in the recent diagnostic framework of SCD proposed in 2014, SCD plus was supplemented as an enrichment strategy to specify features to better identify patients with SCD who have preclinical AD, including the following: (1) subjective decline in memory rather than other domains of cognition, (2) onset of SCD within the last 5 years, (3) age at onset of SCD > 60 years, (4) particular concerns (worries) associated with SCD, (5) feelings of worse performance than others of the same age-group, (6) confirmation of perceived cognitive decline by an informant, and (7) presence of the APOE e4 genotype. 14, 15 Studies that did not consider the features proposed in SCD plus could possibly bear the consequences of inclusion of non-AD related patients with SCD, compromising the power in statistical analyses when differentiating SCD from NCs. We hypothesized that with the implementation of SCD plus in defining patients with SCD, the brain volumetric measures should differentiate SCD from NCs with similar performance as when differentiating aMCI from NCs. In addition, the shared and distinct patterns of brain structural changes in SCD and aMCI as reported in the existing studies are still inconsistent due to the varied inclusion criteria of SCD and the varied measures of brain structural changes. In this regard, we proposed a study with the most recent conceptual framework of SCD with an SCD plus strategy to investigate the brain volumetric differences among patients with aMCI, patients with SCD, and NC participants and to test whether the brain volumetric changes in patients with SCD specified by SCD plus can help distinguish SCD from NCs with similar performance when distinguishing aMCI from NCs using a support vector machine (SVM; a machine learning approach for classification).
Material and Methods Participants
One hundred thirty-two right-handed participants were recruited for this study, including 44 patients with aMCI and 40 patients with SCD from the memory clinic of the Neurology Department, Xuanwu Hospital, Capital Medical University, and 48 NC participants from the local community in Beijing who were recruited by advertisements. Normal control participants were matched in age, gender, and education. Written informed consent was obtained for all these participants. This study was approved by the Medical Research Ethics Committee of XuanWu Hospital.
The inclusion criteria for SCD were based on the recent research criteria proposed in 2014, 2 as follows: (1) selfreported experience of persistent decline in memory within the last 5 years, which was further confirmed by informants according to the strategy of SCD plus; (2) self-reported concerns or worries about cognitive decline (specified in SCD plus); (3) general normal cognition according to objective neuropsychological tests (Montreal Cognitive Assessment [MoCA] >19 for the participants with primary school education or even lower education level, >22 for those with secondary school education level, and >24 for those with university education or even higher education level; Mini-Mental State Examination [MMSE] >17 for the illiteracy participants, >20 for those with primary school education, >24 for those with junior/high school education or even higher education level); and (4) a Clinical Dementia Rating (CDR) score of 0.
The patients with aMCI were diagnosed based on the criteria proposed by Petersen in 2004, 16 which have been described in our previous studies 17, 18 ; that is, (1) presence of a memory complaint; (2) presence of objective memory impairment measured by MMSE, MoCA, and the auditory verbal learning test (AVLT); (3) near-normal performance on general cognition with preserved daily life activities; (4) a CDR score of 0.5; and (5) not meeting the criteria for dementia. The NC participants did not present cognitive decline complaints, and their MMSE, MoCA, and AVLT scores were within the normal range.
In addition, the participants were excluded if they had any of the following conditions: (1) other neurological disorders that could cause cognitive decline; (2) presence of infarcts, infections, or other focal injuries that were visible on MRI; (3) unable to undergo neuropsychological tests or having any contraindications to MRI scanning; (4) major depressive disorder, bipolar disorder, schizophrenia, or any other psychiatric disorders; (5) history of alcohol abuse and dependence, substance abuse, or addiction in the past 2 years; and (6) unable to complete the examinations due to other systemic diseases or uncertainty. All the included participants underwent brain MRI. Detailed demographics and clinical characteristics of the participants are shown in Table 1 . 
Image Acquisition

Image Processing
All the T1-weighted MRI scans were processed with AccuBrain ® (BrainNow Medical Technology Limited, Shenzhen, China), an automatic brain segmentation and quantification software program based on statistical prior anatomical knowledge by experienced radiologists with 5 years of experience. 19 In detail, the segmentation of AccuBrain was based on a multiatlas pool that was derived from many brain MR images acquired from different scanners together with prior anatomical information from radiologists of the brain structures to be delineated. In a recent validation study based on a standard data set from the European Alzheimer's Disease Consortium-Alzheimer's Disease Neuroimaging Initiative Harmonized Protocol, where manual hippocampal segmentation references were available, AccuBrain achieved the best performance among the existing automatic brain segmentation tools (with a mean dice similarity coefficient of 0.89 compared with the ground truths from manual segmentation). 19 Here, we selected 18 quantified brain regions from AccuBrain that were cognitive-relevant for the analysis, including the lateral ventricle, third ventricle, bilateral hippocampus, amygdala, frontal lobe, occipital lobe, temporal lobe, parietal lobe, cingulate lobe, and insular areas.
The volumes of these structures were divided by the intracranial volume (ICV) for each participants as a normalization process for the subsequent analyses. Here, the ICV was defined as volume within the cranium, including the brain, meninges, and cerebrospinal fluid. 20 
Statistical Analysis
We performed an analysis of variance (ANOVA) with Bonferroni post hoc tests to compare the continuous demographic characteristics and the regional brain volumetric measures among the 3 groups. Kruskal-Wallis tests with post hoc Dunn tests were performed to compare the categorical characteristics (eg, gender and CDR) of the participants in the 3 groups. Regarding the comparisons in regional brain volumes, the false discovery rate (FDR) correction with q < .05 was used to further adjust the P values generated from post hoc tests of the ANOVA for multiple comparisons regarding different brain regions.
Furthermore, we tested whether the individual volumetric measures of different brain regions or their combinations could distinguish aMCI versus NC, SCD versus NC, and aMCI versus SCD using a linear SVM with C-SVM implementation. 21, 22 In detail, each of the 18 brain regional volumes was used once as an independent feature (predictor) in an SVM model to differentiate pairs of groups, and we entered all the brain volumes of 18 brain regions in another SVM model for the same classification tasks. To achieve a reliable estimation of the classification performance between pairs of groups, we performed repeated stratified nested 10-fold cross-validations with a 3-way split of data 23, 24 for each of the aforementioned 19 SVM models.
For example, for the classification of SCD and NC groups (with a specific set of features as predictors), we first divided the data of the SCD group and NC group into 10 folds. We then randomly extracted 1 portion (or fold) from both groups and combined them together to make a mixed fold. In this way, the data were integrated into 10 mixed folds (M 1 , M 2 , . . . , M 10 ), where each fold had the same proportion of SCD and NC participants (ie, "stratified"). With this set of data, we used 1 mixed fold (eg, M 1 ) for testing, and the remaining 9 folds (eg, M 2 , M 3 , . . . , M 10 ) for training and validation (ie, "nested"). Specifically, the data of the remaining 9 folds were further divided into 10 subfolds (S 1 , S 2 , . . . , S 10 ), with 9 subfolds used for training and 1 subfold for validation. The validation process was realized during a grid search of the optimal parameter C (box constraint) for an SVM model from 2 À10 to 2 10 . In detail, with a specific parameter C, each subfold (S i , i ¼ 1 . . . 10) was used once for validation and the others for training, and we evaluated the validation performance based on the average classification accuracy (ACC) and area under the curve (AUC) of the 10 validations. In this way, we searched for the optimal parameter C that maximized the ACC and AUC during validation.
Here, the ACC was the number of correctly classified samples divided by the total number of samples. The AUC was the area under the receiver operating characteristics (ROC) curve, where the ROC curve was obtained by plotting the true-positive rates versus the false-positive rates for all possible thresholds of the estimated posterior probability of each sample to be predicted. 25, 26 The value of AUC varies from 0.5 representing no discrimination to 1.0 representing perfect discrimination in a classification. 27 On the one hand, the ACC depended on the selected threshold (ie, the predicted class labels in SVM), whereas the AUC considered all possible thresholds based on probability estimations, thus providing a sense of ranking for each sample rather than a simple class label. 25 On the other hand, the AUC also suffered from some drawbacks such as ignoring the goodness-of-fit of the model 28 ; therefore, it was not recommended as an independent measure of model performance. 29 As both the ACC and AUC are widely used in neuroimaging-based classification studies of prodromal AD stages, 13 we considered both as outcome measures for a reliable evaluation of the model performance and an easier comparison with previous studies.
The parameter C that achieved the best performance in validation was treated as the optimal parameter to retrain the model with the data that combined the training set and validation set (ie, S 1 , S 2 , . . . , S 10 or M 2 , M 3 , . . . , M 10 ). The resulting model was used to predict the class labels of the testing set (ie, M 1 ) that was never used for training or validation. Of note, each of the 10 mixed folds (M i , i ¼ 1, 2, . . . ,10) were once held apart for testing while the remainder were used for training and validation, and we recorded the generated ACC and AUC of the 10 evaluations on unseen data. The aforementioned stratified nested cross-validation was further performed 20 times (ie, "repeated") regarding random partitions of the data for the mixed 10-folds (M 1 , M 2 , . . . , M 10 ), and the classification performance in testing was evaluated by the average ACC and AUC of the resulting 200 independent evaluations. The repeated random partitions of the data and full use of each fold for testing helped to minimize the effect of the random variation on the evaluation of model performance. 30 Regarding the classification of MCI versus NC and MCI versus SCD, the analysis procedure was similar.
Results
The demographic characteristics of the participants are shown in Table 1 . Age, gender, and education level were matched for the 3 groups (NC, SCD, and aMCI; P > .05 for each group comparison). When comparing the SCD and NC groups, there were no significant differences in MoCA and MMSE. Additionally, the patients with SCD had significantly lower immediate recall scores of AVLT than the NC participants (P ¼ .005). In addition, patients with aMCI had significantly lower MMSE, MoCA, and AVLT, and higher CDR than the NC group and SCD group (P < .001).
The results from the ANOVA with post hoc Bonferroni tests and FDR correction are shown in Table 2 , and the trends of the volumetric differences among the 3 groups were indicated from the error bars, as shown in Figures 1-3 . Most of the predefined brain regions showed significant volumetric differences between the aMCI and NC groups and between SCD and NC groups (corrected P < .05). There was a significant volumetric difference in the lateral ventricle for aMCI versus NC but not for SCD versus NC. Regarding the comparison between aMCI and SCD, only the volume ratios of the right hippocampus, left amygdala, and left temporal lobe showed a weak difference (corrected P < .10), where patients with aMCI had more severe atrophy than patients with SCD in these structures.
The binary classification performance for the 3 groups of participants are provided in Table 3 , and the models with relatively good performance (ACC > 80% in any binary classification) are also shown in Figure 4 . Regarding the classification of aMCI versus NC and SCD versus NC, the SVM models that included the volume ratios of multiple brain regions as predictors (model 19) achieved better performance than the models that only considered the volume ratio of an individual region as the predictor (model 1 * model 18). In the SVM models with multiple brain regions considered, the performance of the classification between SCD and NC (ACC: 94.51%, AUC: 0.9776) was as good as that of the classification between aMCI and NC (ACC: 95.90%, AUC: 0.9924). In addition, 2 SVM models with individual volumetric features (left occipital lobe and right temporal lobe) also achieved high performance (ACC > 90%, AUC > 0.90) in the classifications of aMCI versus NC and SCD versus NC.
When it came to the classification between aMCI and SCD, the ACC was generally less than 63% and the AUC was less than 0.71. The SVM model that included the volumetric measures of multiple brain regions (ACC ¼ 54.95%, AUC ¼ 0.6080) performed no better than several models with individual volumetric features (eg, bilateral hippocampus, bilateral amygdala, and left temporal lobe).
Discussion
In this study, we investigated the volumetric difference of typical brain regions among patients with SCD, who were specified by SCD plus, patients with aMCI, and NC participants. The brain regions with significant volumetric differences found in patients with aMCI compared to NC participants were generally reproduced in patients with SCD. In detail, atrophy in the bilateral hippocampus, amygdala, frontal lobe, occipital lobe, temporal lobe, cingulate lobe, and insular region was found in both patients with aMCI and SCD. All these atrophy patterns found in patients with aMCI were in line with the previous studies. [31] [32] [33] [34] Atrophy of the hippocampus, amygdala, frontal lobe, and temporal lobe in patients with SCD has also been reported, 10, 35, 36 and the remaining atrophy patterns in patients with SCD identified in our study coincided with the regionspecific alterations of memory processing found in a functional MRI study. 37 In addition, we found relatively larger ventricle structures in patients with aMCI than NC participants (which was reported previously) 38 but not in patients with SCD. For the first time, we compared the volumetric difference of predefined brain regions between patients with aMCI and SCD. In general, there were no significant volumetric differences between the 2 groups for the predefined brain regions, which was in line with a previous study using a density map-based (voxel-based morphometry) approach. 8 We only identified relatively more severe atrophy in patients with aMCI than patients with SCD (P < .10 after FDR correction) in the bilateral hippocampus, amygdala, and left temporal lobe ( Table 2 , Figures  1 and 2) . These results, together with the enlarged ventricles found in patients with aMCI but not in patients with SCD, may provide further evidence to support SCD as a transitional period between normal aging and aMCI before possible progression to AD. 4, 39 Additionally, we investigated the severity or sensitivity of brain volumetric changes in differentiating the 3 groups from one another. In the classification analyses, we achieved very high accuracy to distinguish aMCI from NC and SCD from NC when using the volumetric information of multiple brain regions as features (with ACC > 94% and AUC > 0.97 in both classifications). These results outperformed the existing studies that used predefined region-based methods to classify aMCI versus NC (ACC < 90%, AUC < 0.93) 40, 41 and the studies that achieved the best performance in aMCI versus NC classification by using the density map-based approach (ACC ¼ 90%) and cortical surface-based approach (AUC ¼ 0.95). 11, 40 More importantly, we also achieved much better performance than a recent study that also used a predefined region-based approach to distinguish SCD from NC (ACC < 68%), 7 which was observed either in our model with the volume ratios of multiple brain regions as the predictors or in the several other models that use the volume ratio of a single region as the predictor (Figure 4) . In fact, for the first time, we demonstrated that automated MRI volumetry could differentiate SCD from NC with a very similar performance to that of differentiating aMCI from NC. In addition, we also applied the volumetric measures to distinguish aMCI from SCD, and none of the models achieved ideal classification performance as that of aMCI versus NC and SCD versus NC, which was in line with the general similar atrophy pattern between aMCI and SCD, identified in the group comparison analysis.
Of note, we applied a robust approach for parameter tuning and evaluation of the classification performance of the SVM models, that is, the repeated nested cross-validations 23, 24 that used a 3-way split of the data set to keep the test data set unseen during model training. This method helped to achieve reliable Abbreviations: L, left; aMCI, amnestic mild cognitive impairment; NC, normal control; R, right; SCD, subjective cognitive decline; SD, standard deviation.
a
The P values shown here were generated from an analysis of variance with post hoc Bonferroni corrections and are further adjusted with FDR correction for the multiple brain regions involved in comparisons.
estimation of the generalization abilities of the classification models and to minimize the bias and variation in the metrics of model estimation based on our study cohort. As several classification models (aMCI vs NC and SCD vs NC) with a single predictor (ie, the volume ratio of a single region) in this study also outperformed the existing studies; these ideal classification performances may derive from the patient inclusion criteria and the brain segmentation tool that we used. First, we applied the recently proposed strategy SCD plus and only included the patients who had worries about their memory decline with informant confirmation of their memory decline. 2 These inclusion criteria potentially screened for the inclusion of patients with more severe cognitive deficits and a higher possibility of AD conversion in our study compared to the other studies investigating brain atrophy of SCD, in which informant confirmation and/or worries about the memory decline for the diagnosis of SCD were missing. 7, 12 In fact, the patients with SCD with worries about their cognitive decline were at much higher risk of conversion to AD and thus might have more severe brain atrophy than the patients with SCD without worries. 15 These findings were important, as the patients with SCD identified with the recent concept of SCD plus in our study (which indicated higher risk of conversion from SCD to AD) would be of more clinical interest. Furthermore, as the degree of cognitive deficits in the patients with aMCI (as measured by MMSE) was similar to most of the studies that investigated the classification of aMCI versus NC, 11, 12, 41 the enhanced classification performance of aMCI versus NC (as well as SCD vs NC) in our study may also result from the brain segmentation tool (AccuBrain) that we used, which has presented the highest accuracy in hippocampus segmentation to date among the existing automated image processing tools. 19 In fact, when using the hippocampus volume as the only predictor in the classifications of aMCI versus NC and SCD versus NC, a previous study had an AUC of less than 0.68, 7 whereas in our study, the AUC was more than 0.95. Furthermore, this result indicated that with the help of an accurate and robust automatic brain segmentation tool, the predefined region-based approach (using volumetric information of either individual or multiple brain regions) can achieve comparable sensitivity in measuring brain structural changes with density map-based and cortical surface-based approaches and even better performance in differentiating aMCI and SCD from NC. There are several limitations in this study that should be considered. First, the sample size in our study was relatively small for each group of participants (aMCI, SCD, and NC), which indicated that the results from our study might not be generalizable to a cohort with significantly different demographic characteristics. Future studies with a larger sample size could combine MRI volumes and general demographic characteristics to achieve more generalizable results in clinical practice. Second, detailed neuropsychological tests were not available in our study cohort to comprehensively evaluate the cognitive functioning of the participants. In addition, the SCD group in this study met 4 of the 7 features of SCD plus but not all of the features as proposed in the consensus paper on SCD in preclinical AD. 2 For example, the information about the presence of the APOE e4 genotype was not available for the patients with SCD. However, the validation of the proposed features of SCD plus is still ongoing, and which item to reject remains an open question.
14 In fact, this study confirmed that by using part of the features of SCD plus (ie, subjective decline in memory rather than other domains of cognition, onset of SCD within the last 5 years, particular concerns or worries associated with SCD, and confirmation of perceived cognitive Similar with Model 4 (P ¼ 0.587) but significantly higher than the other models with P < 0.001. d Significantly higher than all the other models with P < 0.001. e Similar with Model 9 (P ¼ 0.372) but significantly higher than the other models with P < 0.001. decline by an informant), we could also include patients with SCD with more severe brain atrophy (ie, indicating higher risk of AD conversion) than the previous studies that did not apply SCD plus features. The impact of the other features of SCD plus still needs to be validated in the future. Furthermore, we did not include patients with SCD who failed to match the major features of SCD plus (eg, patients without concerns or worries about their SCD) as an additional reference group; therefore, a direct comparison in brain atrophy was not available between the patients with SCD with and without SCD plus features. Finally, this study was based on cross-sectional data, and the follow-up data of the subjects were not available regarding their potential conversion from SCD to aMCI/ AD or aMCI to AD. As not all participants identified as SCD or aMCI will have further progression, future studies should aim to investigate the atrophy patterns of the converters (patients who converted from SCD to aMCI/AD or from aMCI to AD at follow-ups) and whether automated MRI volumetry can help identify the participants with higher risk of subsequent conversion. 15 In conclusion, we identified the shared and distinct atrophy patterns between patients with SCD and aMCI using automated volumetric measures of predefined brain regions, and the patients with SCD were identified, as proposed recently, by using the strategy of SCD plus. The brain atrophy of several temporal lobe structures found in patients with aMCI was less severe or absent in patients with SCD, which provided further evidence about the transitional role of SCD between NC and aMCI prior to further progression to AD. In addition, we further demonstrated that atrophy in patients with SCD (with worries of cognitive decline and informant confirmation as specified by SCD plus) was severe enough to differentiate them from NC participants using the predefined region-based approach, and the classification performance was similar to that of aMCI versus NC. The results of the study need to be validated with a larger sample size, and future efforts should aim to investigate the prediction power of automated MRI volumetry in the conversion from SCD to aMCI or AD.
